GlassScriptPhysician profile
Marco A Martinez
NPI 1629700869
$3,250.14
in general payments reported to CMS, 2019-2025
20 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $378 · 2024: $1,769 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $351.37 | 2024-2025 | Farxiga, Airsupra |
| Viiv Healthcare Company | $350.17 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $290.54 | 2024-2025 | Descovy |
| Abbvie INC. | $240.12 | 2024-2025 | |
| Abbott Laboratories | $211.23 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $187.92 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Inspire Medical Systems, INC. | $182.60 | 2024 | Inspire |
| Boston Scientific Corporation | $179.90 | 2024 | Embold Fibered, Therasphere Y90 Glass Microspheres 10 Gbq, Flexima |
| Lilly USA, LLC | $77.66 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.61 | 2024-2025 | Jardiance |
| Pfizer INC. | $76.74 | 2024 | |
| Astellas Pharma US INC | $67.90 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $34.49 | 2024-2025 | Austedo Xr, Ajovy |
| Glaxosmithkline, LLC. | $34.41 | 2024 | Arexvy, Trelegy Ellipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.22 | 2024 | Voquezna |
| Ardelyx, INC. | $26.32 | 2024 | Ibsrela |
| Sumitomo Pharma America, INC. | $22.65 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $16.05 | 2024 | Nexletol |
| Phadia US INC. | $14.51 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.